137 related articles for article (PubMed ID: 38861131)
1. A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development.
Broglio K; Cooner F; Wu Y; Xiao M; Xue XQ; Lowen M; Ikhapoh I; He P
Ther Innov Regul Sci; 2024 Jun; ():. PubMed ID: 38861131
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
Bretz F; Schmidli H; König F; Racine A; Maurer W
Biom J; 2006 Aug; 48(4):623-34. PubMed ID: 16972714
[TBL] [Abstract][Full Text] [Related]
4. Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial.
Duputel B; Stallard N; Montestruc F; Zohar S; Ursino M
Stat Methods Med Res; 2023 May; 32(5):963-977. PubMed ID: 36919403
[TBL] [Abstract][Full Text] [Related]
5. When is a seamless study desirable? Case studies from different pharmaceutical sponsors.
Cuffe RL; Lawrence D; Stone A; Vandemeulebroecke M
Pharm Stat; 2014; 13(4):229-37. PubMed ID: 24891148
[TBL] [Abstract][Full Text] [Related]
6. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
7. RESTART trial design: two-stage seamless transition design with operational considerations.
Yi M; Zhuo B; Cooner F
J Biopharm Stat; 2023 Nov; 33(6):820-829. PubMed ID: 36653753
[TBL] [Abstract][Full Text] [Related]
8. Use of Seamless Study Designs in Oncology Clinical Development- A Survey Conducted by IDSWG Oncology Sub-team.
Dong Y; Paux G; Broglio K; Cooner F; Gao G; He W; Gao L; Xue X; He P
Ther Innov Regul Sci; 2024 Jun; ():. PubMed ID: 38909174
[TBL] [Abstract][Full Text] [Related]
9. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
10. Practical characteristics of adaptive design in phase 2 and 3 clinical trials.
Sato A; Shimura M; Gosho M
J Clin Pharm Ther; 2018 Apr; 43(2):170-180. PubMed ID: 28850685
[TBL] [Abstract][Full Text] [Related]
11. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.
Hobbs BP; Barata PC; Kanjanapan Y; Paller CJ; Perlmutter J; Pond GR; Prowell TM; Rubin EH; Seymour LK; Wages NA; Yap TA; Feltquate D; Garrett-Mayer E; Grossman W; Hong DS; Ivy SP; Siu LL; Reeves SA; Rosner GL
J Natl Cancer Inst; 2019 Feb; 111(2):118-128. PubMed ID: 30561713
[TBL] [Abstract][Full Text] [Related]
12. A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges.
Chen YH; Gesser R; Luxembourg A
Clin Trials; 2015 Feb; 12(1):84-90. PubMed ID: 25278227
[TBL] [Abstract][Full Text] [Related]
13. A seamless phase II/III design with dose optimization for oncology drug development.
Li Y; Zhang Y; Mi G; Lin J
Stat Med; 2024 Jun; ():. PubMed ID: 38845095
[TBL] [Abstract][Full Text] [Related]
14. Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives.
Sverdlov O; Wong WK
Ther Innov Regul Sci; 2014 Sep; 48(5):601-612. PubMed ID: 30231452
[TBL] [Abstract][Full Text] [Related]
15. Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review.
Palermos D; Sergentanis TN; Gavriatopoulou M; Malandrakis P; Psaltopoulou T; Terpos E; Ntanasis-Stathopoulos I
J Clin Med; 2022 Dec; 11(23):. PubMed ID: 36498749
[TBL] [Abstract][Full Text] [Related]
16. Adaptive seamless designs with interim treatment selection: a case study in oncology.
Carreras M; Gutjahr G; Brannath W
Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
[TBL] [Abstract][Full Text] [Related]
17. Optimal sample size division in two-stage seamless designs.
Berry LR; Marion J; Berry SM; Viele K
Pharm Stat; 2024 Apr; ():. PubMed ID: 38676420
[TBL] [Abstract][Full Text] [Related]
18. Criteria for dose-finding in two-stage seamless adaptive design.
Zheng J; Chow SC
J Biopharm Stat; 2019; 29(5):908-919. PubMed ID: 31495271
[TBL] [Abstract][Full Text] [Related]
19. Seamless phase II/III design: a useful strategy to reduce the sample size for dose optimization.
Jiang L; Yuan Y
J Natl Cancer Inst; 2023 Sep; 115(9):1092-1098. PubMed ID: 37243720
[TBL] [Abstract][Full Text] [Related]
20. Optimal seamless phase 2/3 oncology trial designs based on Probability of Success (PoS).
Teng Z; Liang L; Liu G; Liu Y
Stat Med; 2018 Dec; 37(28):4097-4113. PubMed ID: 30084110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
